EXCIVA TARGETEDDRUGRESCUE Trademark

Trademark Overview


On Wednesday, November 22, 2017, a trademark application was filed for EXCIVA TARGETEDDRUGRESCUE with the United States Patent and Trademark Office. The USPTO has given the EXCIVA TARGETEDDRUGRESCUE trademark a serial number of 87695736. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, August 8, 2025. This trademark is owned by EXCIVA UG (haftungsbeschränkt). The EXCIVA TARGETEDDRUGRESCUE trademark is filed in the Pharmaceutical Products category with the following description:

Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparat...
exciva targeteddrugrescue

General Information


Serial Number87695736
Word MarkEXCIVA TARGETEDDRUGRESCUE
Filing DateWednesday, November 22, 2017
Status710 - CANCELLED - SECTION 8
Status DateFriday, August 8, 2025
Registration Number5667395
Registration DateTuesday, January 29, 2019
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 10, 2018

Trademark Statements


Description of MarkThe mark consists of The trademark is the logo of the company comprising a turquoise blue crescent, royal blue "exciva", turquoise blue "TARGETED", royal blue "DRUG", turquoise blue "RESCUE", and two royal blue curved wings above and below the text.
Goods and ServicesAllergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders
Pseudo MarkEXCIVA TARGETED DRUG RESCUE
Indication of Colors claimedThe color(s) Turquoise blue and royal blue is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 8, 2025
Primary Code005
First Use Anywhere DateMonday, July 2, 2018
First Use In Commerce DateMonday, July 2, 2018

Trademark Owner History


Party NameEXCIVA GMBH
Party Type31 - New Owner After Registration
Legal Entity Type27 - NOT AVAILABLE
AddressVERNON HILLS 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Trademark Events


Event DateEvent Description
Tuesday, December 5, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 6, 2017NOTICE OF DESIGN SEARCH CODE E-MAILED
Saturday, November 25, 2017NEW APPLICATION ENTERED
Tuesday, April 3, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, April 3, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 10, 2018PUBLISHED FOR OPPOSITION
Wednesday, November 14, 2018TEAS STATEMENT OF USE RECEIVED
Wednesday, November 14, 2018USE AMENDMENT FILED
Saturday, December 1, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, March 7, 2018ASSIGNED TO EXAMINER
Wednesday, March 7, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 21, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 10, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 5, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 26, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, January 29, 2019REGISTERED-PRINCIPAL REGISTER
Sunday, March 8, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, March 8, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, March 8, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, March 8, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sunday, March 8, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, March 8, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, June 11, 2020REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD
Saturday, July 4, 2020TEAS SECTION 7 REQUEST RECEIVED
Tuesday, November 3, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, January 29, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, June 11, 2024REGISTERED - SEC. 7 REQUEST ABANDONED
Saturday, December 1, 2018STATEMENT OF USE PROCESSING COMPLETE
Tuesday, December 25, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 7, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, May 13, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, November 4, 2020POST REGISTRATION ACTION MAILED - SEC. 7
Friday, August 8, 2025CANCELLED SEC. 8 (6-YR)